Blood stage malaria vaccine
AssigneesGriffth University, La Trobe University
InventorsMichael Good, Terry W. Spithill, Moses Lee
Life of this patent
Estimating the term…
Abstract
An immunogenic composition for use as a blood-stage malaria vaccine, a method of producing the immunogenic composition and a method of treatment of malaria are provided. The immunogenic composition includes isolated or purified merozoites, or red blood cells infected with merozoites, treated with centanamycin or tafuramycin A. The immunogenic composition does not include an adjuvant. A single dose of the immunogenic composition is sufficient to protect an animal against subsequent malaria infection by the same isolate, strain or species of Plasmodium used in the immunogenic composition, or by one or more heterologous isolates, strains or species of Plasmodium.
Claims18
An immunogenic composition comprising blood-stage malaria parasites or red blood cells infected with said blood-stage malaria parasites that have been pre-treated with tafuramycin A or an analog or derivative thereof, prior to administration to a subject, said pre-treatment being effective to attenuate, but not kill said blood stage malaria, and an immunologically acceptable carrier, diluent and/or excipient, wherein tafuramycin A or an analog or derivative thereof is a compound of Formula I:
- wherein,
- R1 is OH;
- R2 and R3 form a fused furan ring;
- Y is —CH— and forms a five-membered ring with R4;
- X is selected from chloro, bromo, iodo, mesylate, tosylate, thio, ammonium, C1-6 alkylsulfonyl and C1-6 alkylsulfoxyl;
- R4 is a —CH2— group bonded to Y to form a five-membered ring;
- and
- R5 is
Dependencies are inferred from the claim text.